Submitted:
26 April 2025
Posted:
27 April 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Design
2.2. Study Population
2.3. Definitions
2.4. Study Variables
2.5. Analysis Plan and Statistical Analysis
3. Results
3.1. Whole Population
3.2. Factors Associated with ICU Crude Mortality According to General Linear Model (GLM)
3.3. Linear Model (GLM) Validation
3.4. Development of the GLM Model with Correction of Class Imbalance
3.5. Factors Associated with ICU Mortality According to No-Linear Model (Random Forest)
3.6. Non-Linear Model (RFc) Validation
3.7. Patient Classification by Model
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
References
- Centers for Disease Control and Prevention (CDC). COVID-19 Case Surveillance Public Use Data. [Internet] 2021. Available from: https://data.cdc.gov (access 24 April 2025).
- Viboud, C.; Simonsen, L. Global mortality of 2009 pandemic influenza A H1N1. Lancet Infect. Dis. 2012, 12, 651–653. [Google Scholar] [CrossRef] [PubMed]
- Simonsen, L.; Spreeuwenberg, P.; Lustig, R.; Taylor, R.J.; Fleming, D.M.; Kroneman, M.; et al. Global Mortality Estimates for the 2009 Influenza Pandemic from the GLaMOR Project: A Modeling Study. PLoS Med. 2013, 10, e1001558. [Google Scholar] [CrossRef]
- World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard – Deaths. [Internet] 2023. Available from: https://data.who.int/dashboards/covid19/deaths (accessed on 24 April 2025).
- Mathieu, E.; Ritchie, H.; Rodés-Guirao, L.; Appel, C.; Gavrilov, D.; Giattino, C.; Hasell, J.; Macdonald, B.; Dattani, S.; Beltekian, D.; Ortiz-Ospina, E.; Roser, M. COVID-19 Pandemic. Our World in Data [Internet] 2020. https://ourworldindata.org/coronavirus (accessed on 24 April 2025).
- Ferrer, R. COVID-19 Pandemic: the greatest challenge in the history of critical care. Med. Intensiva 2020, 44, 323–324. [Google Scholar] [CrossRef] [PubMed]
- Díaz, E.; Martin-Loeches, I.; Canadell, L.; Vidaur, L.; Suárez, D.; Socias, L.; et al. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. J. Infect. 2012, 64, 311–318. [Google Scholar] [CrossRef] [PubMed]
- Martin-Loeches, I.; Rodríguez, A.; Bonastre, J.; Zaragoza, R.; Sierra, R.; Marques, A.; et al. Severe pandemic (H1N1)v influenza A infection: Report on the first deaths in Spain. Respirology 2011, 16, 78–85. [Google Scholar] [CrossRef]
- Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X.; et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020, 382, 1708–1720. [Google Scholar] [CrossRef]
- Carbonell, R.; Urgelés, S.; Rodríguez, A.; Bodí, M.; Martín-Loeches, I.; Solé-Violán, J.; et al. Mortality comparison between the first and second/third waves among 3,795 critical COVID-19 patients with pneumonia admitted to the ICU: A multicentre retrospective cohort study. Lancet Reg. Health Eur. 2021, 11, 100243. [Google Scholar] [CrossRef]
- Díaz, E.; Rodríguez, A.; Martin-Loeches, I.; Lorente, L.; Del Mar Martín, M.; Pozo, J.C.; et al. Impact of obesity in patients infected with 2009 influenza A(H1N1). Chest 2011, 139, 382–386. [Google Scholar] [CrossRef]
- Álvarez-Lerma, F.; Marín-Corral, J.; Vilà, C.; Masclans, J.R.; Martín-Loeches, I.; Barbadillo, S.; et al. Characteristics of patients with hospital-acquired influenza A (H1N1)pdm09 virus admitted to the intensive care unit. J. Hosp. Infect. 2017, 95, 200–206. [Google Scholar] [CrossRef]
- Martin-Loeches, I.; Papiol, E.; Rodríguez, A.; Díaz, E.; Zaragoza, R.; Granada, R.M.; et al. Acute kidney injury in critically ill patients affected by influenza A (H1N1) virus infection. Crit. Care 2011, 15, R66. [Google Scholar] [CrossRef]
- Oliva, I.; Ferré, C.; Daniel, X.; Cartanyà, M.; Villavicencio, C.; Salgado, M.; et al. Risk factors and outcome of acute kidney injury in critically ill patients with SARS-CoV-2 pneumonia: a multicenter study. Med. Intensiva 2024, 48, 1–10. [Google Scholar] [CrossRef]
- Rodríguez, A.H.; Ruiz-Botella, M.; Martín-Loeches, I.; Jiménez Herrera, M.; Solé-Violán, J.; Gómez, J.; et al. Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain. Crit. Care 2021, 25, 63. [Google Scholar] [CrossRef]
- Benítez, I.D.; de Batlle, J.; Torres, G.; González, J.; de Gonzalo-Calvo, D.; Targa, A.D.; et al. Prognostic implications of comorbidity patterns in critically ill COVID-19 patients: A multicenter, observational study. Lancet Reg. Health Eur. 2022, 18, 100422. [Google Scholar] [CrossRef] [PubMed]
- Karasneh, R.A.; Khassawneh, B.Y.; Al-Azzam, S.; Al-Mistarehi, A.H.; Lattyak, W.J.; Aldiab, M.; et al. Risk Factors Associated with Mortality in COVID-19 Hospitalized Patients: Data from the Middle East. Int. J. Clin. Pract. 2022, 2022, 9617319. [Google Scholar] [CrossRef] [PubMed]
- Ribas, V.J.; Vellido, A.; Ruiz-Rodríguez, J.C.; Rello, J. Severe sepsis mortality prediction with logistic regression over latent factors. Expert Syst. Appl. 2012, 39, 1937–1943. [Google Scholar] [CrossRef]
- Vellido, A.; Ribas, V.; Morales, C.; Ruiz-Sanmartín, A.; Ruiz-Rodríguez, J.C. Machine learning in critical care: State-of-the-art and a sepsis case study. Biomed. Eng. Online 2018, 17 (Suppl 1), 135. [Google Scholar] [CrossRef]
- Aushev, A.; Ripoll, V.R.; Vellido, A.; Aletti, F.; Pinto, B.B.; Herpain, A.; et al. Feature selection for the accurate prediction of septic and cardiogenic shock ICU mortality in the acute phase. PLoS ONE 2018, 13, e0199089. [Google Scholar] [CrossRef]
- Johnson, A.E.W.; Ghassemi, M.M.; Nemati, S.; Niehaus, K.E.; Clifton, D.A.; Clifford, G.D. Machine Learning and Decision Support in Critical Care. Proc. IEEE 2016, 104, 444–466. [Google Scholar] [CrossRef]
- Carbonell, R.; Moreno, G.; Martín-Loeches, I.; Gomez-Bertomeu, F.; Sarvisé, C.; Gómez, J.; et al. Prognostic Value of Procalcitonin and C-Reactive Protein in 1608 Critically Ill Patients with Severe Influenza Pneumonia. Antibiotics 2021, 10, 350. [Google Scholar] [CrossRef]
- Rodríguez, A.H.; Avilés-Jurado, F.X.; Díaz, E.; Schuetz, P.; Trefler, S.I.; Solé-Violán, J.; et al. Procalcitonin (PCT) Levels for Ruling-Out Bacterial Coinfection in ICU Patients with Influenza: A CHAID Decision-Tree Analysis. J. Infect. 2016, 72, 143–151. [Google Scholar] [CrossRef]
- Carbonell, R.; Urgelés, S.; Salgado, M.; Rodríguez, A.; Reyes, L.F.; Fuentes, Y.V.; et al. Negative Predictive Value of Procalcitonin to Rule Out Bacterial Respiratory Co-Infection in Critical COVID-19 Patients. J. Infect. 2022, 85, 374–381. [Google Scholar] [CrossRef] [PubMed]
- World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA 2013, 310, 2191–2194. [Google Scholar] [CrossRef]
- Cuschieri, S. The STROBE Guidelines. Saudi J. Anaesth. 2019, 13 (Suppl 1), S31–S34. [Google Scholar] [CrossRef]
- Uyeki, T.M.; Bernstein, H.H.; Bradley, J.S.; Englund, J.A.; File, T.M.; Fry, A.M.; et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clin. Infect. Dis. 2019, 68, 895–902. [Google Scholar] [CrossRef]
- World Health Organization. Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease is Suspected: Interim Guidance, 13 March 2020. World Health Organization, 2020. Available online: https://apps.who.int/iris/handle/10665/331446 (accessed on 24 April 2025).
- Martin-Loeches, I.; Schultz, M.J.; Vincent, J.L.; Alvarez-Lerma, F.; Bos, L.D.; Solé-Violán, J.; et al. Increased Incidence of Co-Infection in Critically Ill Patients with Influenza. Intensive Care Med. 2017, 43, 48–58. [Google Scholar] [CrossRef] [PubMed]
- Kellum, J.A.; Lameire, N.; Aspelin, P.; Barsoum, R.S.; Burdmann, E.A.; Goldstein, S.L.; et al. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. Suppl. 2012, 2, 1–138. [Google Scholar] [CrossRef]
- Knaus, W.A.; Draper, E.A.; Wagner, D.P.; Zimmerman, J.E. APACHE II: A Severity of Disease Classification System. Crit. Care Med. 1985, 13, 818–829. [Google Scholar] [CrossRef]
- Vincent, J.L.; Moreno, R.; Takala, J.; Willatts, S.; De Mendonça, A.; Bruining, H.; et al. The SOFA (Sepsis-Related Organ Failure Assessment) Score to Describe Organ Dysfunction/Failure. Intensive Care Med. 1996, 22, 707–710. [Google Scholar] [CrossRef]
- Menardi, G.; Torelli, N. Training and Assessing Classification Rules with Imbalanced Data. Data Min. Knowl. Discov. 2014, 28, 92–122. [Google Scholar] [CrossRef]
- Lunardon, N.; Menardi, G.; Torelli, N. ROSE: A Package for Binary Imbalanced Learning. R J. 2014, 6, 79–89. [Google Scholar] [CrossRef]
- Huang, H.; Cai, S.; Li, Y.; Li, Y.; Fan, Y.; Li, L.; et al. Prognostic Factors for COVID-19 Pneumonia Progression to Severe Symptoms Based on Earlier Clinical Features: A Retrospective Analysis. Front. Med. 2020, 7, 557453. [Google Scholar] [CrossRef] [PubMed]
- Zhu, Z.; Cai, T.; Fan, L.; Lou, K.; Hua, X.; Huang, Z.; et al. Clinical Value of Immune-Inflammatory Parameters to Assess the Severity of Coronavirus Disease 2019. Int. J. Infect. Dis. 2020, 95, 332–339. [Google Scholar] [CrossRef] [PubMed]
- Gong, J.; Ou, J.; Qiu, X.; Jie, Y.; Chen, Y.; Yuan, L.; et al. A Multicenter Study Using the Risk Nomogram in COVID-19 Patients. J. Med. Virol. 2020, 92, 2453–2461. [Google Scholar] [CrossRef]
- Aloisio, E.; Chibireva, M.; Serafini, L.; Pasqualetti, S.; Falvella, F.S.; Dolci, A.; et al. A Comprehensive Appraisal of Laboratory Biochemistry Tests as Major Predictors of COVID-19 Severity. Arch. Pathol. Lab. Med. 2020, 144, 1457–1464. [Google Scholar] [CrossRef] [PubMed]
- Liu, Q.; Song, N.C.; Zheng, Z.K.; Li, J.S.; Li, S.K. Laboratory Findings and a Combined Multifactorial Approach to Predict Death in Critically Ill Patients with COVID-19: A Retrospective Study. Epidemiol. Infect. 2020, 148, e129. [Google Scholar] [CrossRef]
- Reina Reina, A.; Barrera, J.M.; Valdivieso, B.; Gas, M.E.; Maté, A.; Trujillo, J.C. Machine Learning Model from a Spanish Cohort for Prediction of SARS-COV-2 Mortality Risk and Critical Patients. Sci. Rep. 2022, 12, 7736. [Google Scholar] [CrossRef]
- Pourhomayoun, M.; Shakibi, M. Predicting Mortality Risk in Patients with COVID-19 Using Machine Learning to Help Medical Decision-Making. Smart Health 2021, 20, 100178. [Google Scholar] [CrossRef]
- Alballa, N.; Al-Turaiki, I. Machine Learning Approaches in COVID-19 Diagnosis, Mortality, and Severity Risk Prediction: A Review. Inform. Med. Unlocked 2021, 24, 100622. [Google Scholar] [CrossRef]
- Hernández-Cárdenas, C.M.; Choreño-Parra, J.A.; Torruco-Sotelo, C.; Jurado, F.; Serna-Secundino, H.; Aguilar, C.; et al. Clinical Risk Factors for Mortality Among Critically Ill Mexican Patients with COVID-19. Front. Med. 2021, 8, 699607. [Google Scholar] [CrossRef]
- Cornelius, E. Covid-19 Mortality Prediction Using Machine Learning-Integrated Random Forest Algorithm under Varying Patient Frailty; Master's Thesis, Illinois State University, 2021. [CrossRef]
- Banoei, M.M.; Dinparastisaleh, R.; Zadeh, A.V.; Mirsaeidi, M. Machine-Learning-Based COVID-19 Mortality Prediction Model and Identification of Patients at Low and High Risk of Dying. Crit. Care 2021, 25, 328. [Google Scholar] [CrossRef]
- Wang, M.; Li, W.; Wang, H.; Song, P. Development and Validation of Machine Learning-Based Models for Predicting Healthcare-Associated Bacterial/Fungal Infections Among COVID-19 Inpatients: A Retrospective Cohort Study. Antimicrob. Resist. Infect. Control 2024, 13, 42. [Google Scholar] [CrossRef] [PubMed]




| Variable | Whole population (n= 8,902) |
Survival (n=6,608) |
Non-survival (n=2,294) |
p-value |
| General | ||||
| Age, median (Q1-Q3) years Age cut-off > 58 years, n (%) |
60 (49-70) 5177(58.1) |
58 (48-68) 3473 (52.6) |
67 (57-74) 1704 (74.3) |
<0.001 <0.001 |
| Male sex, n (%) | 5855 (65.8) | 4248 (64,3) | 1607 (70.1) | <0.001 |
| APACHE II, median (Q1-Q3) APACHE II cut-off > 13, n (%) |
14 (10-19) 5309 (59.6) |
13 (10-17) 3536 (53.5) |
17 (13-22) 1773 (77.3) |
<0.001 <0.001 |
| SOFA score, median (Q1-Q3) SOFA cut-off > 4, n (%) |
5 (3-7) 6274 (70.5) |
4(3-7) 4299 (65.1) |
6(4-9) 1975 (86.1) |
<0.001 <0.001 |
| GAP UCI, median (Q1-Q3) GAP UCI cut-off > 1 day, n (%) |
1 (1-3) 6804 (76.4) |
1 (1-3) 5085 (77.0) |
2 (0-4) 1719 (74.9) |
<0.001 0.053 |
| GAP Diagnosis, median (Q1-Q3) GAP diagnosis cut-off > 3 days, n (%) |
4 (1-7) 5413 (60.8) |
3 (1-7) 3943 (59.7) |
4 (1- 7) 1470 (64.1) |
0.012 <0.001 |
| > 2 fields with infiltrations in chest X-ray, n (%) | 5343 (60.0) | 3775 (57.1) | 1568 (68.4) | <0.001 |
| Antiviral vaccine, n (%) | 1333 (14.9) | 885 (13.4) | 448 (19.5) | <0.001 |
| Shock at ICU admission, n (%) | 3549 (39.9) | 2286 (34.6) | 1263 (55.1) | <0.001 |
| Laboratory | ||||
| White blood cells count, median (Q1-Q3) x103 White blood cells count cut-off < 8.5 x103, n (%) |
8.6 (5.7-12.5) 4405 (49.5) |
8.5 (5.7-12.1) 3351 (50.7) |
9.0 (5.8-13.7) 1054 (45.9) |
<0.001 <0.001 |
| Lactate dehydrogenase, median (Q1-Q3) U/L Lactate dehydrogenase cut-off > 500 U/L, n (%) |
542 (403-687) 5157 (57.9) |
524 (378-665) 3593 (54.4) |
590 (458-749) 1564 (68.2) |
<0.001 <0.001 |
| C reactive protein, median (Q1-Q3) mg/dL C reactive protein cut-off >20 mg/dL , n (%) |
19.6 (9.8-34.7) 4387 (49.3) |
19.0(9.5-34.4) 3184 (48.2) |
21.1 (10.4-35.4) 1203 (52.4) |
0.001 <0.001 |
| Procalcitonin, median (Q1-Q3) ng/mL Procalcitonin cut-off >0.80 ng/mL, n (%) |
0.88 (0.20-5.67) 4606 (51.7) |
0.83 (0.20-5.08) 3350 (50.7) |
1.04 (0.23-8.20) 1256 (54.8) |
<0.001 0.001 |
| Lactate, median (Q1-Q3) mmol/L Lactate cut-off > 2mmol/L, n (%) |
2.0 (1-4-3.3) 4660 (52.3) |
2.0 (1.3-3.2) 3369 (51.0) |
2.2 (1.4-3.8) 1291 (56.3) |
<0.001 <0.001 |
| Creatinine, median (Q1-Q3) mg/dL Creatinine cut-off >0.85 mg/dL, n (%) |
0.89 (0.7-1.2) 4841 (54.4) |
0.85 (0.68-1.12) 3330 (50.4) |
1.01 (0.75-1.50) 1511 (65.9) |
<0.001 <0.001 |
| D dimer, median (Q1-Q3) ng/mL D dimer cut-off > 2700 ng/mL, n (%) |
3071 (971-6604) 4663 (52.4) |
2716 (900- 6000) 3314 (50.2) |
4180 (1200-8680) 1349 (58.8) |
<0.001 <0.001 |
| creatine phosphokinase, median (Q1-Q3) U/L creatine phosphokinase cut-off > 200 U/L, n (%) |
216 (100-420) 4707 (52.9) |
210 (97-414) 3433 (52.0) |
234 (111-442) 1274 (55.5) |
0.001 0.003 |
| Comorbidities | ||||
| Diabetes mellitus, n (%) | 1196 (13.4) | 756 (11.4) | 440 (19.2) | <0.001 |
| Asthma, n (%) | 698 (7.7) | 556 (8.4) | 142 (6.2) | 0.001 |
| COPD, n (%) | 1281 (14.4) | 936 (14.2) | 345 (15.0) | 0.32 |
| Chronic heart disease, n (%) | 623 (7.0) | 418 (6.3) | 205 (8.9) | <0.001 |
| Chronic liver disease, n (%) | 595 (6.7) | 357 (5.4) | 238 (10.4) | <0.001 |
| Pregnancy, n (%) | 480 (5.4) | 399 (6.0) | 81 (3.5) | <0.001 |
| Obesity, n (%) | 3046 (34.2) | 2256 (34.1) | 790 (34.4) | 0.81 |
| Human immunodeficiency virus, n (%) | 144 (1.6) | 107 (1.6) | 37 (1.6) | 1.00 |
| Hematologic disease, n (%) | 436 (4.8) | 237 (3.6) | 199 (8.7) | <0.001 |
| Immunosuppression, n (%) | 711 (8.0) | 401 (6.0) | 310 (13.5) | <0.001 |
| Treatment | ||||
| Steroids, n (%) | 5275 (59.2) | 3746 (56.7) | 1529 (66.7) | <0.001 |
| Antibiotics (AB) at ICU admission, n (%) | 7410 (83.2) | 5428 (82.1) | 1982 (86.4) | <0.001 |
| Appropriate empiric AB treatment, n (%) | 951 ((10.7) | 671 (10.2) | 280 (12.2) | 0.007 |
| High flow nasal cannula at admission, n (%) | 1438 (16.1) | 1138 (17.2) | 300 (13.1) | <0.001 |
| Invasive mechanical ventilation, n (%) | 4252 (47.8) | 2751 (41.6) | 1501 (65.4) | <0.001 |
| Most common aetiology of coinfection | ||||
| Coinfection, n (%) | 1211 (100) | 810 (12.3) | 401 (17.5) | <0.001 |
| Methicillin- sensitive S. aureus (MSSA), n (%) | 172 (14.2) | 111 (13.7) | 61 (15.2) | 0.47 |
| Pseudomonas aeruginosa, n (%) | 143 (11.8) | 82 (10.1) | 61 (15.2) | 0.01 |
| Klebsiella spp. N (%) | 85 (7.0) | 60 (7.4) | 25 (6.2)) | 0.45 |
| Aspergillus spp, n (%) | 78 (6.5) | 33 (4.0) | 45 (11.2) | <0.001 |
| E. coli, n (%) | 69 (5.7) | 43 (5.3) | 26 (6.3) | 0.40 |
| Methicillin- resistant S. aureus (MRSA). n (%) | 56 (4.6) | 33 (4.0) | 23 (5.7) | 0.19 |
| Acinetobacter spp, n (%) | 17 (1.4) | 4 (0.5) | 13 (3.2) | <0.001 |
| Outcomes | ||||
| ICU LOS, median (Q1-Q3) days | 13 (6-23) | 12 (6-23) | 14 (7-24) | 0.03 |
| Acute Kidney injury, n (%) | 1435 (16.1) | 855 (12.9) | 580 (25.3) | <0.001 |
| GLM Model | Random Forest Model | |||
|---|---|---|---|---|
| Variable | OR | 95%CI | Decrease Accuracy | Decrease Gini |
| Age > 58 years | 2.03 | 1.74-2.36 | 34.9% | 79.2% |
| APACHE II > 13 points | 1.72 | 1.48-2.02 | 19.1% | 88.1% |
| SOFA > 4 points | 1.47 | 1.23-1.76 | 26.0% | 65.1% |
| Shock | 1.27 | 1.09-1.47 | 16.4% | 77.4% |
| Hematologic disease | 1.67 | 1.26-2.22 | 19.5% | 39.4% |
| Obesity | 1.16 | 1.01-1.32 | ----- | 92.4% |
| Diabetes | 1.37 | 1.14-1.65 | 16.5% | 60.6% |
| Immunosuppression | 1.92 | 1.53-2.42 | 18.9% | 53.0% |
| Steroids | 1.54 | 1.34-1.77 | 12.7% | 81.6% |
| Mechanical ventilation | 1.94 | 1.67-2.25 | 33.0% | 88.1% |
| Myocardial dysfunction | 3.27 | 2.53-4.28 | 47.2% | 63.6% |
| Acute kidney injury | 1.29 | 1.07-1.55 | ---- | ----- |
| > 2 fields with infiltrations in chest X-ray | 1.54 | 1.34-1.77 | 16.8% | 81.3% |
| LDH > 500 U/L | 1.41 | 1.22-1.63 | 11.5% | 79.7% |
| Creatinine > 0.85 mg/dL | 1.33 | 1.14-1.55 | 13.3% | 73.8% |
| Acinetobacter spp. | 9.95 | 2.61-47.8 | ---- | ---- |
| Aspergillus spp. | 2.45 | 1.39-4.33 | 11.2% | ---- |
| Procalcitonin >2ng/mL | ---- | ---- | 23.0% | 68.1% |
| D-dimer > 2700 ng/mL | ---- | ---- | 21.7% | 75.9% |
| Lactate > 2 mmol/L | ---- | ---- | 18.1% | 79.5% |
| COPD | ---- | ---- | 17.4% | 61.3% |
| CPK > 200 U/L | ---- | ---- | 13.1% | 90.6% |
| GAP-Diagnosis > 3 days | ---- | ---- | ---- | 96.9% |
| WBC count < 8.5 x103 | ---- | ---- | ---- | 93.3% |
| Male | ---- | ---- | ---- | 81.3% |
| GAP-ICU < 1day | ---- | ---- | ---- | 77.1% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).